Locations:
SearchAdvertisement
Consult program a valuable tool that benefits both patients and clinicians
Approach resulted in transfusion independence and durable anemia response
Risk increases due to dietary restrictions and menstruation
Study matches momelotinib against danazol
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Momelotinib, a new JAK inhibitor, inches closer to market approval
New research sheds light on mechanism of action in ROP protection
Treat it, but not too aggressively
Advertisement
Advertisement